Back to News
Market Impact: 0.4
Opus Genetics Reports Positive OPGx-BEST1 Data; Plans Potential Phase 3 Trial In 2027
Source: Nasdaq
Healthcare & Biotech
Opus Genetics reported positive 3- and 6-month results from Cohort 1 of its ongoing Phase 1/2 BIRD-1 trial of OPGx-BEST1. The gene therapy is being evaluated in patients with BEST1-related retinal diseases, including Best vitelliform macular dystrophy and autosomal recessive BEST1 disease. Positive early-stage clinical data could support further development of the program and move Opus Genetics shares.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
IRD0.75
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction
- What Is an AI Investment Research Platform?